



ASX Announcement

14th June 2023

Atomo and Newfoundland sign agreement for HIV testing in Europe

SYDNEY, Australia, June 14th, 2023 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce it has entered into an exclusive supply agreement with UK based company Newfoundland Diagnostics Limited (Newfoundland), for HIV rapid testing in Europe. This agreement follows an initial purchase order of HIV Self-Tests worth approximately A\$900,000 received from Newfoundland. (ASX release dated 28th February 2023 - Significant Purchase Order for HIV Self-Tests for Europe).

The agreement sees Newfoundland commit to placing a larger follow-on order worth approximately A\$1.2m prior to 31st December 2023 which, added to the initial order, secures exclusivity for 2024. The agreement is effective immediately and subject to standard termination provisions. At the end of the first year of the agreement, the parties have agreed to negotiate an up to 3-year extension, with increasing indicative annual volumes already agreed between the parties for 2024 and 2025.

Atomo's CEO John Kelly said "We are delighted to have entered into a strategic partnership with Newfoundland and look forward to expanding this partnership beyond HIV testing in the coming months. They have an enviable track record in accessing retail channels where Atomo's tests are ideally suited to consumer use." Mr Kelly added, "We anticipate delivery of the first batch of Newfoundland branded HIV Self-Tests to Europe shortly".

Newfoundland is an emerging leader in the growing European diagnostic consumer-initiated testing market that has arisen out of the COVID pandemic and has established extensive distribution networks in Europe, including recent contracts with leading retailers Tesco and Boots in the UK.

Newfoundland CEO, Mr Frederick Manduca said, "We are extremely proud of our wrap around service, our best-in-class range of diagnostic products and being at the forefront of self-testing in the UK and further afield. We're pleased to partner with Atomo to add rapid HIV testing to our product range and supply them exclusively to the UK and Europe, and we look forward to being able to offer such a crucial test as HIV to our offering.



For more information, please contact:

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com